Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649551 | 0.94 | CASP3 (0.42) | MDM2TLR2SIRT2SIRT1KLKB1 | |
| SCHEMBL29649526 | 0.90 | MDM2 (0.45) | MDM2TLR2SIRT2SIRT1MDM4 | |
| SCHEMBL31681574 | 0.90 | MDM2 (0.45) | MDM2TLR2SIRT2SIRT1MDM4 | |
| SCHEMBL25361941 | 0.90 | MDM2 (0.43) | MDM2TLR2SIRT2SIRT1MDM4 | |
| SCHEMBL25361944 | 0.90 | MDM2 (0.43) | MDM2TLR2SIRT2SIRT1MDM4 | |
| SCHEMBL29649631 | 0.86 | MDM2 (0.43) | MDM2TLR2SIRT2SIRT1MDM4 | |
| SCHEMBL30518584 | 0.86 | PTPN1 (0.45) | MDM2SIRT2SIRT1 | |
| SCHEMBL6158363 | 0.86 | MDM2 (0.57) | MDM2TLR2MDM4TP53 | |
| SCHEMBL436024 | 0.86 | MDM2 (0.57) | MDM2TLR2MDM4TP53 | |
| SCHEMBL31681399 | 0.86 | MDM2 (0.57) | MDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MDM2 942/4885TLR2 3403/4885SIRT2 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.